NEXTBIO CAPITAL MANAGEMENT LP
Q4 2025 Form 13-F
MENLO PARK, DELAWARE
CIK 0002038158
· Institutional investment manager
$170.5M Reported Value Total
Reported value
$170.5M
Quarter over quarter
0.0%
Holdings
23
Top-10 concentration
70.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Ky Phan
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 13, 2026 |
| Form | 13F-HR |
| Reported value | $170.5M |
| Positions | 23 |
| Change in reported value | First reported quarter |
| Top-10 concentration | 70.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
25 | $234.4M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
22 | $217.4M |
|
Q1 2026 13F
Filed May 14, 2026
|
24 | $215.4M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
23 | $170.5M |
Top 20 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | TERN TERNS PHARMACEUTICALS INC | $22.3M | 13.06% |
| 2 | PTGX PROTAGONIST THERAPEUTICS INC | $20.1M | 11.76% |
| 3 | VOR VOR BIOPHARMA INC | $13.1M | 7.67% |
| 4 | ZBIO ZENAS BIOPHARMA INC | $11.7M | 6.86% |
| 5 | STTK SHATTUCK LABS INC | $11.5M | 6.74% |
| 6 | VSTM VERASTEM INC | $10.1M | 5.92% |
| 7 | PVLA PALVELLA THERAPEUTICS INC NE | $8.7M | 5.08% |
| 8 | XENE XENON PHARMACEUTICALS INC | $8.2M | 4.83% |
| 9 | RYTM RHYTHM PHARMACEUTICALS INC | $7.2M | 4.24% |
| 10 | GPCR STRUCTURE THERAPEUTICS INC | $6.6M | 3.85% |
| 11 | IVA INVENTIVA SA | $6.0M | 3.54% |
| 12 | CMPX COMPASS THERAPEUTICS INC | $6.0M | 3.51% |
| 13 | CMPS COMPASS PATHWAYS PLC | $5.2M | 3.05% |
| 14 | ORIC ORIC PHARMACEUTICALS INC | $5.0M | 2.95% |
| 15 | CBIO CRESCENT BIOPHARMA INC. | $4.4M | 2.59% |
| 16 | PCVX VAXCYTE INC | $4.4M | 2.58% |
| 17 | EVMN EVOMMUNE INC | $3.9M | 2.29% |
| 18 | COGT COGENT BIOSCIENCES INC | $3.4M | 2.0% |
| 19 | IRON DISC MEDICINE INC | $3.4M | 1.99% |
| 20 | OCS OCULIS HOLDING AG | $3.0M | 1.75% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.